• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CYP

CYNATA THERAPEUTICS LIMITED - Charts / Financials

6.33% ! 21.0¢
Market Cap $46.32M  !
Healthcare Biotechnology
Add to My Watchlist

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and... Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.More

refresh Created with Sketch. REFRESH
Last update - 10.47am 21/08/2025 (20 minute delay) ?
Day
Open 20.5¢   Day High 21.0¢   Day Low 20.5¢
Daily Volume 82995
Bids   Sellers
Number Price Volume   Number Price Volume
2 20.0¢ 207   2 21.0¢ 41744

Directors & Senior Management

Dr. Kilian Kelly Chief Executive Officer, Managing Director, Director
Dr. Suzanne Lipe Vice President - Partner Engagement
Dr. Jolanta Airey Chief Medical Officer
Dr. Mathias Kroll Chief Business Officer
Mr. Peter Gordon Webse Company Secretary
Dr. Geoffrey E. D. Brooke Independent Non-Executive Chairman of the Board
Ms. Janine Rolfe Director
Dr. Darryl Maher Non-Executive Independent Director
Dr. Paul K. Wotton Non-Executive Independent Director

Data source: Refinitiv

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
21.0¢ 		Change
0.013(6.33%) 		Mkt cap ! $46.32M
Open High Low Value Volume
20.5¢ 21.0¢ 20.5¢ $17.40K 82.99K

Buyers (Bids)

No. Vol. Price($)
2 207 20.0¢
 

Sellers (Offers)

Price($) Vol. No.
21.0¢ 41744 2
View Market Depth
Last trade - 11.08am 21/08/2025 (20 minute delay) ?

Top Stories

ASX Market Open: Earnings galore – and what's reported will dictate bourse swing | Aug 21

Australian shares will open up today, with ASX 200 futures pointing to a +0.14% gain for the local bourse, but it may not hold for long.
Listen: HotCopper Wire Podcast 020 – Forget dreaming, the 9,000s are nearly here Welcome to this week’s HotCopperWire, our market watch podcast! Each week, HotCopper’s senior markets reporter Jonathon Davidson and I take you through the week’s biggest news headlines @ and what they mean for Oz investors.In this Week 33 epis...
ResMed up on bullish analyst notes after solid quarter ResMed (ASX:RMD) is still batting eyelashes at brokers, with Ord Minnett reaffirming its @Buy” rating following what it called a @solid” quarterly performance.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headl...
Mount Gibson books $82M loss, looks to overcome with gold for growth It’s been a tough year for Mount Gibson Iron, with the company today reporting a net loss after tax of $82.2 million for FY25.
Metallium copies Texas playbook to extend US footprint with 2 more e-waste sites Metallium (ASX:MTM) obtains exclusive lease options for sites in Westport and Harrisonburg as it looks to extend State-side operations.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.